Summit Securities Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-200
Closed -$53K – 690
2024
Q1
$53K Buy
+200
New +$47.1K 0.01% 248

Other funds holding MDGL

Summit Securities Group's MDGL Position: Q3 2026 in Review

Summit Securities Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 148 shares — an estimated $79.5K sold.

Summit Securities Group first reported a position in MDGL in Q2 2013 and held it in 4 quarters. The position peaked at $79.5K in Q2 2026. 407 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Summit Securities Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Summit Securities Group sold 148 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $79.5K.
  • Summit Securities Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Summit Securities Group's Madrigal Pharmaceuticals position peaked at $79.5K in Q2 2026.
  • 407 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.